Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Editor’s introduction to the initial issue of the ninth volume of GaBI Journal / Professor Philip D Walson, MD
Importance of the determination of the higher order structure in the in-use stability studies of biopharmaceuticals / Professor Alain Astier, PharmD, PhD
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions / Shon Crampton, BA; Alla Polozova, PhD; Darin Asbury, BS; Alexis Lueras, BS; Paul Breslin, BS; Jane Hippenmeyer, PharmD; Jennifer Litowski, PhD; Monica Goss, PhD
Pharmaceutical pricing policy in Saudi Arabia: findings and implications / Alian A Alrasheedy, BPharm(Hons), MPharm(Clin), PhD, MACP, RPh
Global Challenges in the Manufacture, Regulation and International Harmonisation of GMP and Quality Standards for Biopharmaceuticals / Chong Hock Sia; Ming Kian Sia; Lai Wah Chan
Tailored development program of Pelmeg®, a biosimilar pegfilgrastim / Karsten Roth, Hendrik Wessels, Josef Höfler, Ulrike Scholz, Dirk Lehnick
Current trends for biosimilars in the Latin American market / Esteban Ortiz-Prado, Jorge Ponce-Zea, Eduardo Vasconez, Diana Castillo, Diana Checa, Nathalia Rodríguez-Burneo, Felipe Andrade, Damaris Intriago, Claudio Galarza-Maldonado
It is time to change US trade policy to foster access to medicines / Maria Fabiana Jorge, MBA
Policy recommendations for a sustainable biosimilars market: lessons from Europe / Professor Philip J Schneider, MS, FASHP, FFIP; Michael S Reilly, Esq
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD
Overview of non-innovator biological products in India / GR Soni, PhD
Top developments in biosimilars during 2019 / GaBI Journal Editor
Biosimilars markets: US and EU compared / GaBI Journal Editor
Clinical trials for trastuzumab biosimilars / GaBI Journal Editor
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.